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ABSTRACT 
 
Malaria is one of the most abundant parasitic diseases in the world affecting many of the poorest 
economies. The estimated prevalence is 300 to 700 million clinical episodes each year with up to 3 
million deaths. Piperaquine replaced chloroquine as the first line treatment in China for Plasmodium 
falciparum malaria in the 1970s and was used as mass prophylaxis until the emergence of resistance in the 
1990s. It has recently been the object of renewed interest as a partner drug in artemisinin-based 
combination therapy. Artekin® is a fixed oral combination of dihydroartemisinin and piperaquine 
showing excellent efficacy and tolerability against multi-resistant Plasmodium falciparum malaria. Only a 
limited number of studies have addressed the clinical pharmacokinetics of piperaquine, none of which 
have addressed metabolism. Despite its extensive use no published information is available about the 
non-clinical pharmacokinetics or drug metabolism in animals.  
The bioanalytical tools used in this thesis were nuclear magnetic resonance, liquid chromatography, 
quantitative and qualitative mass spectrometry. Data analysis was conducted using conventional 
statistics, population based pharmacokinetic modeling, individual pharmacokinetic modeling and non-
compartmental analysis.  
The results present a new systematic approach for choosing a regression model during 
bioanalytical method validation that can be a useful tool for finding the optimal regression model (paper 
I). It incorporates predictability of independent quality control samples as well as the calibration curve 
fit. This approach was used to find the best regression model during the development and validation of 
a sensitive and selective bioanalytical method for quantification of piperaquine in urine by automated 
solid-phase extraction and isocratic liquid chromatography (paper II).  
Five human urinary metabolites of piperaquine were identified and their molecular structures 
characterized in two healthy male volunteers after an oral single dose of the dihydroartemisinin-
piperaquine combination (paper III). The major metabolites are a carboxyl acid cleavage product and a 
N-oxidated piperaquine product.  
The rat appears to be a suitable animal model for non-clinical in vivo studies since piperaquine 
pharmacokinetic properties and metabolites are similar to those found in humans (paper IV). The 
absolute oral bioavailability was estimated to approximately 50%. The low between-animal variability in 
plasma concentrations after intravenous administration suggests absorption to be critical for between-
animal variability in drug exposure. Piperaquine displayed a low biliary clearance with less than 1% of 
the total dose excreted by this route. Enterohepatic circulation would not contribute significantly to a 
prolongation of the terminal half-life.  
Piperaquine elimination half-life might be underestimated due to inadequate assay sensitivity 
and/or duration of sampling in published information (paper V). This should be considered when 
establishing the duration of follow-up and the assessment of relapse in clinical studies. The population 
pharmacokinetics of piperaquine was characterized in 98 patients in Thailand with uncomplicated 
Plasmodium falciparum malaria, ranging from 3 to 55 years of age (paper VI). The study confirms that 
piperaquine exhibits considerable inter-individual pharmacokinetic variability, has a very large apparent 
volume of distribution, and a slow elimination phase. Pharmacokinetic modeling suggests that despite 
having a smaller central volume of distribution and slower elimination than adults, the children in this 
study had lower piperaquine concentrations in the therapeutically important period immediately 
following treatment. If this is confirmed in other malaria affected regions, then consideration should be 
given to increase the weight adjusted dosage in children. No pharmacokinetic differences could be seen 
between the two investigated study treatment regimens and further support the use of a simplified, once 
daily treatment, regimen to improve treatment adherence and efficacy.  
Overall, this thesis has contributed to a better understanding of the bioanalysis, drug metabolism 
and pharmacokinetics of piperaquine which may contribute to its future safe and efficacious clinical use 
as an antimalarial. 
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